SUTRO BIOPHARMA, INC. (STRO) - Dilution Analysis

10-Q filing | 16.6M shares outstanding

S-3 filing: Sutro Biopharma, Inc. is filing an S-3 to offer common stock, preferred stock, debt securities, warrants, subscription rights, and units up to an aggregate amount of $300 million.

8-K filing: Stock split 1-for-10 | Outstanding: 84,869,864 → 8,519,392

10-Q filing | 84.9M shares outstanding

10-Q filing | 84.6M shares outstanding

10-Q filing | 83.1M shares outstanding

10-K filing | 76.8M shares outstanding

10-Q filing | 82.0M shares outstanding

10-Q filing | 81.2M shares outstanding

10-Q filing | 81.8M shares outstanding

8-K filing: Sutro Biopharma, Inc. entered into an underwriting agreement to issue and sell 14,478,764 shares of its common stock at $5.18 per share, with gross proceeds estimated at $75.0 million, intending to use the net proceeds for general corporate purposes. ($75.0M proceeds)

8-K filing: Sutro Biopharma, Inc. entered into an agreement with Ipsen Biopharmaceuticals, Inc. for the purchase of 4,827,373 shares of Sutro's common stock at a price representing a 17% premium to the VWAP for $25 million. ($25.0M proceeds)

10-K filing | 60.2M shares outstanding

S-3 filing: Sutro Biopharma, Inc. may offer up to $300.0 million aggregate dollar amount of shares of its common stock or preferred stock, debt securities, warrants to purchase its common stock, preferred stock or debt securities, subscription rights to purchase its common stock, preferred stock or debt securities and/or units consisting of some or all of these securities.

10-Q filing | 60.6M shares outstanding

10-Q filing | 60.3M shares outstanding

10-Q filing | 58.7M shares outstanding

10-K filing | 60.2M shares outstanding

10-Q filing | 52.3M shares outstanding

10-Q filing | 47.0M shares outstanding

10-Q filing | 46.9M shares outstanding

POS AM filing: Sutro Biopharma, Inc. may offer up to $350,000,000 aggregate dollar amount of shares of their common stock or preferred stock, debt securities, warrants to purchase their common stock, preferred stock or debt securities, subscription rights to purchase their common stock, preferred stock or debt securities and/or units consisting of some or all of these securities. Common stock offered by them having an aggregate offering price of up to $100 million through an at the market offering.

10-K filing | 46.4M shares outstanding

10-Q filing | 46.2M shares outstanding

10-Q filing | 46.1M shares outstanding

10-Q filing | 46.1M shares outstanding

10-K filing | 45.9M shares outstanding

8-K filing: Sutro Biopharma, Inc. entered into an underwriting agreement to issue and sell 6,000,000 shares of its common stock at a public offering price of $21.00 per share, with an option for the underwriters to purchase up to an additional 900,000 shares, with estimated net proceeds of approximately $118.0 million. ($126.0M proceeds)

10-Q filing | 37.9M shares outstanding

10-Q filing | 35.9M shares outstanding

8-K filing: Sutro Biopharma, Inc. entered into an underwriting agreement to issue and sell 11,000,000 shares of its common stock at a price of $7.75 per share, with an option for the underwriters to purchase an additional 1,650,000 shares. ($85.25M proceeds)

10-Q filing | 23.2M shares outstanding

10-K filing | 23.1M shares outstanding

8-K filing: Sutro Biopharma, Inc. issued warrants to lenders, Oxford Finance LLC and Silicon Valley Bank, exercisable for 81,257 shares of the company's common stock at an exercise price of $9.23 per share, in connection with a loan and security agreement.